|
Emerald Coast Research
Group Ph. (850) 415-0251 Fax (850) 415-6462 Medical Director: Dean Watson, M.D. |
|
Year |
Phase |
Disease |
Protocol |
Contract |
Enrolled |
Investigators/ Coordinators |
|
1999-
Oct. 2001 Completed |
|
Hypertension |
Omapatrilat Hypertension Trial in
Subjects Uncontrolled on Calcium Channel Blocker Therapy |
|
|
Sub. – Coord. – K. Schroeder |
|
1999-
Oct. 2001 Completed |
|
Hypertension |
Omapatrilat Hypertension Trial in
Subjects uncontrolled on Ace Inhibitor Therapy |
|
|
|
|
2000-2001 Completed |
|
Cardiovascular |
PRINCE Trial-Pravastatin
Inflammation/CRP Evaluation in Primary and Secondary Prevention in
Cardiovascular Events |
|
|
PI – Greg Sloan, MD Coord. – K. Schroeder |
|
2000-
ongoing |
III |
Type II Diabetes |
|
|
|
PI – Greg Sloan, MD Sub. – Sub. – Coord. – K. Schroeder Coord. – T. Martin |
|
Mar. 2001- Completed |
III |
Type II Diabetes |
DepoMed |
|
|
PI – Greg Sloan, MD Cood. – K. Schroeder Coord. – T. Martin |
|
Aug.
2001-Oct. 2002 Completed |
IIb |
Hypertension |
Aventis |
|
|
PI – Greg Sloan, MD Coord. – K. Schroeder Coord. – T. Martin |
|
Aug.
2001- Completed |
IIb |
Hypertension |
Bristol-Myers Squibb OCTAVE |
|
|
PI – Greg Sloan, MD Coord.-K. Schroeder |
|
Nov.
2001- ongoing |
III |
Type II Diabetes |
Bristol-Myers Squibb |
|
|
PI – Greg Sloan, MD Coord. – K. Schroeder Coord. – T. Martin |
|
Sept.
2002 – ongoing |
III |
Cardiovascular |
Sanofi-Synthelabo: CHARISMA –
Plavix vs. ASA, Atherothrombotic Prevention study |
|
75 |
PI – Greg Sloan, MD Sub. – Sub. – Sub.- Wayne Campbell, MD Coord. – K. Schroeder Coord. – Tracy Martin |
|
Mar.
2000-June 2000 |
IV |
Hypertension |
LOGIC trial – Hypertension study
with Lotrel |
|
|
PI – Greg Sloan, MD Sub.- Wayne Campbell, MD Sub. – Sub. – Coord. – K. Schroeder |
|
April
2003- ongoing |
III |
Type II Diabetes |
Bristol-Myers Squibb CV168-021 Study drug in Combination with
Glyburide Therapy in Subjects with Type II DM Who Have Inadequate Glycemic
Control on Sulfonylurea Therapy Alone |
|
|
PI – Greg Sloan, MD Sub. – Sub. – Sub.-Hugh VanLandingham, MD Sub.-Lisa Clark, MD Sub.-Patrick Conrad, MD Sub.-Jason Griffin, MD Coord. – K. Schroeder Coord.- T. Martin Coord. – Coord. – D. Williams Coord.- K. Krasinski Coord.- H. Barrentine |
|
April
2003 – ongoing |
III |
Type II Diabetes |
Bristol-Myers Squibb CV168-022 Study drug in Combination with
Metformin Therapy in Subjects with Type II DM Who Have Inadequate Glycemic
Control on Metformin Therapy Alone |
|
|
PI – Greg Sloan, MD Sub. – Sub. – Sub.-Hugh VanLandingham, MD Sub.-Lisa Clark, MD Sub.-Patrick Conrad, MD Sub.-Jason Griffin, MD Coord. – K. Schroeder Coord.- T. Martin Coord. – Coord. – D. Williams Coord.- K. Krasinski Coord.- H. Barrentine |
|
Dec.
2003 – ongoing |
IV |
Erectile Dysfunction |
Bayer REALISE |
|
|
PI – Karl Hempel, MD PI – Gary Winchester, MD PI -Hugh VanLandingham, MD PI – PI – Les Wilson, MD PI – Michelle Stevens, MD Coord. - Coord. – K. Krasinski |
|
Sept
2003- onging |
III |
Type II Diabetes |
BMS CV168-018 |
|
|
PI-Dr. Sloan Sub-Dr. Stevens Sub- Dr. Erwin-Wilson |
|
Nov.
2003 – ongoing |
III
|
Type II Diabetes
|
Bristol-Myers Squibb CV168-025 Study drug vs. Pioglitazone in
Combination with Metformin Therapy in Subjects with Type II DM Who Have
Inadequate Glycemic Control on Metformin Therapy Alone |
|
|
PI- Dr.Sloan
Sub- Dr. Hempel Sub- Dr. Winchester Sub- Dr. VanLandingham |
|
2004-ongoing |
|
Hypertension |
Novartis |
|
|
PI-Dr. Fox PI-Dr. PI-Dr. Banks PI-Dr. |
|
2004-ongoing |
|
Type II Diabetes |
Novartis |
|
|
PI-Dr. Hempel PI-Dr. PI-Dr. Stevens PI-Dr. Dorman PI-Dr. Fulmer PI-Dr. PI-Dr. Sloan PI-Dr. |
|
2004-ongoing |
|
Type II Diabetes |
BMS CV168-048 |
|
|
PI-Dr. PI-Dr. |
|
2004-ongoing |
|
Prostate Cancer |
GlaxoSmithKline |
|
|
PI-Dr. Sloan PI-Dr. Banks PI-Dr. |
|
2004-ongoing |
|
Dyspepsia |
Novartis |
|
|
PI-Dr. PI-Dr. Dorman PI-Dr. Banks PI-Dr. PI-Dr. Stevens PI-Dr. Sloan PI-Dr. Fulmer PI-Dr. Fox PI-Dr. VanLandingham PI-Dr. |
|
2004-ongoing |
|
Overactive Bladder
|
Pfizer
|
|
|
PI-Dr. Sloan
|
|
2004-ongoing |
|
Type II Diabetes
|
BMS CV177-008
|
|
|
PI-Dr. Sloan
PI-Dr. PI-Dr. Stevens PI-Dr. Fox |
|
2004-ongoing |
|
Overactive Bladder
|
Pfizer
|
|
|
PI-Dr.
|